CORAL SPRINGS, Florida, November 5, 2014 /PRNewswire/ --
Cannabis industry forecasts billions in revenue as United States moves towards legalization and MMJ Companies focus on new plans, joint ventures and development of innovative Marijuana products. Companies in Focus Today are: New Colombia Resources, Inc. (OTCQB: NEWC), Neutra Corp. (OTC: NTRR), Creative Edge Nutrition, Inc. (OTC: FITX), Tauriga Sciences, Inc. (OTC: TAUG) and Cannabis Science, Inc. (OTC: CBIS).
New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce plans to spin out its Sannabis S.A.S medical hemp based products company and create an independent U.S. traded reporting publicly traded company. John Campo, President, stated: "Our management team is focused on our core business of developing company coal reserves and industrial aggregate operations. By allowing Sannabis SAS to become an independent public company it will be able to develop its own medical based management team. Additionally Sannabis will have one mission the development of its innovative medical products based on scientific research using unique strains of Cannabis manufactured on the TOEZ Indian Reservation in Colombia. The Company plans to issue shares of Sannabis S.A.S. as a dividend to Shareholders.
After the spinoff Sannabis S.A.S. will operate as an independent company and develop its own medical research staff and funding to further the commercialization of its products. Sannabis S.A.S. aims to become the first company to legally import hemp and medical marijuana products to the U.S. from Colombia. Operations will include patent applications, obtaining medical approvals, and further research and product development. Sannabis SAS believes that the specific strain of hemp being produced on the TOEZ Indian reservation may creates a unique medical opportunity for many people who may find benefit from various hemp based product derivates.
Neutra Corp. (OTCQB: NTRR) recently announced it is finalizing plans for its first commercial production run of the cutting-edge Diamond Anvil Vapor Pen just as analysts are predicting the cannabis industry will not only be legal, but have more annual revenue than the NFL by 2020. Greenwave Advisors, a cannabis-focused research and analysis firm, recently projected federal legalization of the herb in the next six years, which would push first-year countrywide revenues to an estimated $35 billion, surpassing the annual revenue of the NFL. Even without full federal legalization, Greenwave still projects $21 billion in legal cannabis revenues, however, the firm believes 12 states and the District of Columbia will have legalized recreational cannabis by 2020, with medical cannabis being available in 37 states. Currently 23 states have legalized medical cannabis and two states have legalized recreational cannabis use.
Creative Edge Nutrition, Inc. (OTCPink: FITX), a nutritional supplement company, develops, markets, and sells nutraceuticals and health supplements. It offers a range of capsules, tablets, and powders, as well as science based products in weight management, specific nutrition challenges, energy, and fitness categories. The company's products comprise HYPER INFUSION, a pre work-out catalyst; AMINO PLEX, a intra-workout recovery catalyst; CENTRO PLEX, an advanced meal replacement product; ALPHA DRIVE to enhance free testosterone levels; VASOBOLIC, a stimulant free nitric oxide pre-cursor; INOVA, a pre-workout supplement; REDEMPTION; FREE REIGN to increase free testosterone; ROGUE, a muscle builder; THYROZINE, a mood elevating thermogenic; HYPE, a high intensity thermogenic; and REGIME, a physique enhancement product. It also provides natural products, such as Hemp Nutra tea, coffee additives, and slimming tea. On Tuesday, FITX closed up 2.7% on over 19.1 million shares traded.
Tauriga Sciences, Inc. (OTCQB: TAUG), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that it has signed a non-binding MOU with Japan-based iFlow, Ltd. ("iFlow") to distribute and sell three new Tauriga-branded natural wellness products to the Japan, Taiwan and Hong Kong regions (the "Territory"). iFlow is an innovative and entrepreneurial Asian marketing and distribution company with motivational products in health, lifestyle, education, business and finance. If a definitive agreement is reached, the partnership between the companies would enable Tauriga to reach Asian customers with an interest in natural healing. The intent of the parties is for the initial focus of the partnership to be on two different formulations of Tauriga's proprietary TopiCanna topical cannabis cream and on Tauriga's CannaCaviar brand of small soft gel supplements. In compliance with Japanese medical marijuana law, all three products would use oil that has been extracted from the stalk of the cannabis plant and that is higher in CBD (cannabidiol) and low in THC, hence providing wellness and healing properties without psychoactive effects. If the initial phase of the proposed partnership is successful in establishing the Tauriga natural wellness brand in the Territory, the two companies plan to extend the agreement to include additional Tauriga products, such as Tauriga's new line of natural dietary supplements.
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is very pleased with the laboratory analytical reports it recently received. The testing of the cannabis harvested using EU certified as well as its own unique strains produced end results indicating that whole extracts to be produced will contain upward of 20% CBD and less than 10% THC. Furthermore, other unique identifiers are present that require multiple authentications based on their significant nature. These numbers are significant based on usage information and expected treatment regimes for many of the Company targeted ailments. The Company continues investigating both its unique cannabinoid strains as well as promising strains from around the world for multiple pre-clinical drug development programs targeting Cancer, Neurological Disorders, and a few other targeted critical ailments to be announced.
News 
Market Data 
Discover 
AI
